A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.

📅 PUBMED DAILY TRIAGE — 2026-03-28

Window: 2026-03-27T09:00:00Z → 2026-03-28T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: 12 High priority: 2 | Standard: 8 | Low/archive: 1 | Unsolicited finds: 1 Run status: SUCCESS

🔴🟠 HIGH PRIORITY

TR-2026-03-28-001 · PMID 41895279 · Molecular insights into early malignant transition of hepatocellular carcinoma · 8/10 · Published in Cancer Cell; first multi-institutional genomic/immunological profiling of premalignant-to-malignant HCC transition, identifying CNA accumulation as the dominant driver and early immune-evasive phenotypes in 43% of cases — directly relevant to early detection and immunotherapy intervention strategy. 🔴 EARLY_CANCER_DETECTION | Cancer Cell | Fudan/CAS/Mount Sinai | Abstract only

TR-2026-03-28-002 · PMID 41896127 · Development and validation of a deep learning model to predict visual and anatomical prognosis of anti-VEGF therapy for nAMD (KongMing Study) · 8/10 · Prospective nationwide 18-centre Chinese study (n=1,398) in Lancet Digital Health; KongMing deep learning model achieved AUC >0.94 internally and externally, outperforming all ophthalmologist experience levels for predicting treatment outcomes in age-related macular degeneration. 🟢 NEAR_TERM_IMPLEMENTABLE | Lancet Digital Health | PUMCH/Shenzhen University | Abstract only

🟢⚪ STANDARD

TR-2026-03-28-003 · PMID 41895662 · AI-Guided Additive Scoring Model for Differential Diagnosis of Primary Liver Cancer · 6/10 · Diagnostics (liquid biopsy / AI-ML)

EV + serology PRISM score for HCC vs iCCA in LR-M lesions; AUROC ~0.91; n=50 pilot, internal validation only.

TR-2026-03-28-004 · PMID 41895521 · GLP-1 Receptor Agonists and Long-Term Survival After Spontaneous Intracerebral Hemorrhage in Type 2 Diabetes · 7/10 · Treatment Innovation (Cardiovascular-metabolic)

Large PSM cohort (n=5,420); GLP-1 RA post-sICH → 23% lower all-cause mortality at 2 and 5 years; hypothesis-generating real-world evidence.

TR-2026-03-28-005 · PMID 41895364 · Breast arterial calcification on mammography and cardiovascular outcomes in women: a meta-analysis · 7/10 · Diagnostics / Prevention (Cardiometabolic)

Meta-analysis ~30K women; BAC on mammography → pooled HR 1.82 for incident CV events, OR 4.00 for CAD; supports no-added-cost opportunistic CV screening in women.

TR-2026-03-28-006 · PMID 41896084 · Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance · 6/10 · Treatment Innovation (Hematologic malignancies)

MD Anderson retrospective cohort (n=146); Dara-based 2L median PFS2 ~60 months vs ~12 months for IMiD/PI regimens; real-world confirmation in lenalidomide-refractory MM.

TR-2026-03-28-007 · PMID 41896034 · Dissecting histological transformation · 5/10 · Genomics/Precision Medicine

Trends in Cancer review (Varmus/Weill Cornell); frames HT as growing resistance mechanism requiring systematic study; no original data.

TR-2026-03-28-008 · PMID 41895296 · A Clinical Lipidomics Platform: Development and Validation of a High-Throughput LC-MS Assay for Cardiovascular Disease Risk Assessment · 6/10 · Diagnostics (Cardiometabolic)

6-min 270-lipid platform validated in n=994 (BioHEART-CT); Lipidomic Risk Score outperforms Framingham in intermediate-risk patients; Baker Heart Institute.

TR-2026-03-28-009 · PMID 41895355 · Chemotherapy in dedifferentiated chondrosarcoma: from neoadjuvant to palliative treatment options · 5/10 · Treatment Innovation (Rare disease)

Ultra-rare bone sarcoma review (5-yr OS 7-24%); summarizes CHT landscape; IDH1 inhibition shows limited activity (PFS 1.5 months); high unmet need.

TR-2026-03-28-010 · PMID 41895241 · Estimated pulse wave velocity and its role in ASCVD prevalence and mortality among U.S. adults · 5/10 · Diagnostics / Prevention (Cardiometabolic)

NHANES 2001-2018 (n=34,200); ePWV HR 1.96 all-cause and 2.35 CV mortality per SD increase; supports vascular aging marker use in risk models.

TR-2026-03-28-011 · PMID 41895851 · Comparable anal HPV burden and abnormal cytology in MSM using PrEP and MSM living with HIV · 5/10 · Prevention / Public Health

Belgian cross-sectional (n=298); PrEP MSM bear ~74% HR-HPV rate equivalent to HIV-positive MSM; supports extending anal cancer screening to PrEP population.

💡 UNSOLICITED FINDS

TR-2026-03-28-012 · PMID 41895920 · Single-Molecule Counting for Noninvasive Prenatal Diagnosis of Autosomal Recessive Hearing Loss · 3/10

Proof-of-concept NIPT using cfDNA single-molecule counting for hereditary hearing loss; 96% accuracy in n=50; outside primary watchlist but relevant to cfDNA diagnostics space.

📊 TODAY'S BREAKDOWN

By research category:

Diagnostics: 5 (TR-001, TR-002, TR-003, TR-008, TR-010, TR-012)
Treatment Innovation: 3 (TR-004, TR-006, TR-009)
Prevention: 2 (TR-005, TR-011)
Genomics/Precision Medicine: 1 (TR-007)
Early Detection: 1 (TR-001 — dual-classified)

By evidence maturity:

Exploratory: 6
Validated: 5
Potentially Practice-Changing: 0

By watchlist topic (top):

Cardiovascular-metabolic (GLP-1, SGLT2, cardiometabolic): 4
AI/ML in clinical diagnostics and imaging: 3
Early cancer detection (liquid biopsy, ctDNA, cfDNA): 3
Hematologic malignancies: 2
Precision oncology/genomic medicine: 2
Novel therapeutics (immunotherapy/CAR-T): 2
Rare diseases: 1

By source type:

Peer-reviewed: 12 | Preprint: 0

🔧 RUN NOTES